Papapit TuchindaMatthew BremmerAnthony A. GaspariUniversity of Maryland School of MedicineMahidol University2018-06-112018-06-112012-12-20Dermatology and Therapy. Vol.2, No.1 (2012), 1-9219091722-s2.0-84871160440https://repository.li.mahidol.ac.th/handle/123456789/14412Introduction: Sarcoidosis is a systemic granulomatous disease of unknown cause. The management of sarcoidosis remains problematic. Systemic and topical corticosteroids are the mainstay of therapy but may cause unacceptable side effects. Biologic therapies, such as infliximab, have recently beenproposed asanother treatment option for cutaneous sarcoidosis. Case Report: The authors describe three patients who were diagnosed with cutaneous sarcoidosis with systemic involvement. All of the patients were refractory to conventional therapies but responded to infliximab therapy. Conclusion: Infliximab is an alternative medication for refractory sarcoidosis that has a relatively benign side-effect profile. However, definite indications, dosage, interval, and duration of treatment for cutaneous sarcoidosis are not firmly established. © The Author(s) 2012.Mahidol UniversityMedicineArticleSCOPUS10.1007/s13555-012-0011-9